P/E ratio for Teva Pharmaceutical Industries (TEVA)
P/E ratio as of March 2023 (TTM): -4.12
According to Teva Pharmaceutical Industries's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.11792. At the end of 2021 the company had a P/E ratio of 21.1.
P/E ratio history for Teva Pharmaceutical Industries from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 21.1 | |
| 2019 | -10.7 | 60.27% |
| 2018 | -6.65 | 470.31% |
| 2017 | -1.17 | -100.23% |
| 2016 | 518 | 1351.64% |
| 2015 | 35.7 | 122.07% |
| 2014 | 16.1 | -39.88% |
| 2013 | 26.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 28.3 | -787.26% | 🇨🇭 Switzerland |
 Pfizer PFE | 7.18 | -274.41% | 🇺🇸 USA |
 Sanofi SNY | 18.7 | -554.24% | 🇫🇷 France |
 Merck MRK | 18.7 | -553.18% | 🇺🇸 USA |
 AstraZeneca AZN | 64.8 | -1,674.57% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 4.43 | -207.62% | 🇬🇧 UK |
 Dr. Reddy's RDY | 23.3 | -664.61% | 🇮🇳 India |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.